SCHEMBL7148996

SCHEMBL7148996

CC(C)(C)OC(=O)[C@@H]1C[C@@H](O)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MME P08473 2/20 0.45
ACE P12821 2/20 0.45
ECE1 P42892 2/20 0.45
LMNA P02545 2/20 0.44
CASP3 P42574 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
ACACB O00763 1/20 0.43
AKR1C3 P42330 3/20 0.42
AKR1C1 Q04828 1/20 0.42
POLB P06746 1/20 0.42
MCL1 Q07820 1/20 0.42
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.41
HSD11B1 P28845 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143312 1.00 ALDH1A1 (0.48) ALDH1A1L3MBTL1MEN1KMT2AMME
SCHEMBL6980507 0.88 MME (0.49) ALDH1A1L3MBTL1MEN1KMT2AMME
SCHEMBL5409165 0.88 MME (0.49) ALDH1A1L3MBTL1MEN1KMT2AMME
SCHEMBL7166230 0.88 MME (0.49) ALDH1A1L3MBTL1MEN1KMT2AMME
SCHEMBL7148874 0.88 MME (0.42) ALDH1A1L3MBTL1MEN1KMT2AMME
SCHEMBL7141875 0.88 MME (0.42) ALDH1A1L3MBTL1MEN1KMT2AMME
SCHEMBL7137614 0.85 MME (0.42) ALDH1A1KMT2AMMEACEECE1
SCHEMBL7145366 0.85 MME (0.42) ALDH1A1KMT2AMMEACEECE1
SCHEMBL5415726 0.83 AKR1C3 (0.54) ALDH1A1L3MBTL1MMEACEECE1
SCHEMBL6945225 0.83 AKR1C3 (0.54) ALDH1A1L3MBTL1MMEACEECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885L3MBTL1 3514/4885MEN1 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.